Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

Also called NCT07403669

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07403669
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Sweden (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07403669. Randomized; no masking; primary purpose treatment. Start 2025-10-22 (actual); primary completion 2026-10-22 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
Acronym
CHAPERONE-CKM
Condition
Acute MI
Condition
Heart Failure
Condition
Diabetes Mellitus
Condition
Kidney Disease
Intervention (Other)
CHAPERONE AI
Intervention (Device)
CKMiq AI
Intervention (Other)
Quality of Life
Lead sponsor
Aventyn, Inc. (class: industry)
Collaborator
Dignity Health (class: other)
Collaborator
Arizona Heart Foundation (class: not stated)
Collaborator
Arizona State University (class: other)
Collaborator
University of Arizona (class: other)
Collaborator
University of Phoenix College of Nursing (class: not stated)
Collaborator
Creighton School of Medicine, Phoenix Arizona (class: not stated)
Collaborator
Karolinska University Hospital (class: other)
Collaborator
Partnership for Economic Innovation Arizona (class: not stated)
Collaborator
Kanasu Labs (class: not stated)
Collaborator
Intel Corporation (class: industry)

Record details

Record id
cardio:ct-nct07403669
Content hash
b4b61f682d484a44d3e8ddf2c2719276c7548381d64c6fcbf220a86b4acc6d6c